Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo [Phase 1]

View source ↗

Summary

Forte Biosciences reports a Phase 1 study evaluating FB102 for non-segmental vitiligo is currently recruiting to assess safety and initial efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• FB102

Snippet

Sponsor: Forte Biosciences, Inc. | Conditions: Vitiligo | Phase 1 | Status: RECRUITING